Cyclo Therapeutics Q1 EPS $(0.33) Up From $(0.76) YoY
Cyclo Therapeutics (NASDAQ:CYTH) reported quarterly losses of $(0.33) per share. This is a 56.58 percent increase over losses of $(0.76) per share from the same period last year.
Cyclo Therapeutics Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q4, Cyclo Therapeutics's (NASDAQ:CYTH) reported sales totaled $585.12 thousand. Despite a 27.66% increase in earnings, the company posted a loss of $2.79 million.
Cyclo Therapeutics Files For U.S. Patent Titled ‘METHODS FOR TREATING ALZHEIMER’S DISEASE’
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220220008453%22.PGNR.&OS=DN/20220008453
45 Biggest Movers From Yesterday
Gainers
Puxin Limited (NYSE: NEW) shares surged 80% to close at $0.54 on Wednesday after reporting results for the second quarter.
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers
Cognition Therapeutics (NASDAQ:CGTX) shares rose 14.9% to $6.62 during Wednesday's after-market session. The market value of their outstanding shares is at $145.8 million.